Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Horizon Pharma Stock Was Cut In Half. Then It Tripled

Published 03/05/2019, 06:16 AM
Updated 07/09/2023, 06:31 AM

Horizon Pharma (NASDAQ:HZNP), headquartered in Dublin, Ireland, is a $4.7B biopharmaceutical company operating primarily in the United States. In July 2015, its stock was in the vicinity of $39.50. By May 2017, it was trading under $10 per share.

We first examined Horizon Pharma stock’s prospects in September 2016, when it was searching for direction near the $18 mark. Here is what we found.

Horizon Pharma Elliott Wave analysis

According to our Elliott Wave analysis of HZNP’s weekly logarithmic chart, the rally from under $2 in March 2013 to $39.49 in July 2015 was a textbook five-wave impulse, labeled (1)-(2)-(3)-(4)-(5). This meant the following sharp selloff was probably part of a three-wave (a)-(b)-(c) correction, whose wave (c) down was still remaining.

No matter how good or bad the company’s fundamentals might have been, that wasn’t what we focused on two and a half years ago. The markets are not as rational as some people believe they are. Even the poorest company can go through the roof, and even the strongest can trade in the doldrums sometimes.

Ahead of Horizon Pharma ‘s Elliott Wave Rally

So instead of analyzing the company, we tried to understand the market’s attitude towards it. Back in September 2016, wave (c) was “about to take the stock back to the price area between $9 and $7” and complete the 5-3 wave cycle. The trend was then supposed to resume in the direction of the five-wave impulse. Instead of losing hope, we thought investors should take advantage of this low-risk buying opportunity.

Horizon Pharma climbed to $29.44 last week. The updated chart below visualizes its development since September 2016.

Horizon Pharma Tripled from the Lows in May 2017

Wave (c) dragged the stock down to $9.45. The touted reason for the crash to single digits was the company’s disappointing Q1 2017 report which also included a lowered guidance for the full year. In reality, the stage was set for a plunge in wave (c) long ago.

And just when the outlook was the bleakest, the bulls took the wheel and never looked back. Less than two years later, those who had the courage to buy Horizon Pharma stock below $10 a share multiplied their money by three.

The stock is still below its 2015 high, so we think the bulls’ chances of reaching $40 are quite good. How far can they go past this psychological mark is anyone’s guess at this point.

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.